Skip to main content

A clinical evaluation of the effect of maintaining haemoglobin levels with weekly EPREX®/ERYPO® (Epoetin alfa) in subjects with lymphoid malignancies (Hodgkin’s Disease, Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma) un

A clinical evaluation of the effect of maintaining haemoglobin levels with weekly EPREX®/ERYPO® (Epoetin alfa) in subjects with lymphoid malignancies (Hodgkin’s Disease, Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma) undergoing chemotherapy


CSR Summary

Not Available


NCT Number

Not Available


Primary Citation

Not Available


Data Specification

Not Available


Annotated CRF

Available upon data request approval

Product Info

Generic Name
Epoetin alfa
Product Name
PROCRIT®
Therapeutic Area
Blood and Lymph Conditions
Enrollment
1,000
% Female
N/A
% White
N/A
Product Class
Hematologic Agents
Sponsor Protocol Number
OBE/EPO-INT-02
Data Partner
Johnson & Johnson
Condition Studied
Anemia
Mean/Median Age (Years)
58.9

Supporting Documentation

Collected Datasets
Annotated Case Report Form
Study Phase 
3
Additional Information: 

Three narratives are available upon data request approval for Study OBE-EPO-INT-02: Subjects With Disease Progression, Subjects Who Died, and Subjects with Thrombovascular Events.

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.